Literature DB >> 34648425

A randomized controlled trial of cognitive behavioral therapy for insomnia and PAP for obstructive sleep apnea and comorbid insomnia: effects on nocturnal sleep and daytime performance.

Alice Y Tu1,2, Megan R Crawford3, Spencer C Dawson4, Louis F Fogg5, Arlener D Turner6, James K Wyatt7, Maria I Crisostomo, Bantu S Chhangani8, Clete A Kushida9, Jack D Edinger10, Sabra M Abbott1, Roneil G Malkani1,11, Hrayr P Attarian1, Phyllis C Zee1, Jason C Ong1,12.   

Abstract

STUDY
OBJECTIVES: This study examines the impact of cognitive behavioral therapy for insomnia (CBT-I) and positive airway pressure (PAP) therapy for comorbid insomnia and sleep apnea on nocturnal sleep and daytime functioning.
METHODS: A partial factorial design was used to examine treatment pathways with CBT-I and PAP and the relative benefits of each treatment. One hundred eighteen individuals with comorbid insomnia and sleep apnea were randomized to receive CBT-I followed by PAP, self-monitoring followed by CBT-I concurrent with PAP, or self-monitoring followed by PAP only. Participants were assessed at baseline, PAP titration, and 30 and 90 days after PAP initiation. Outcome measures included sleep diary- and actigraphy-measured sleep, Flinders Fatigue Scale, Epworth Sleepiness Scale, Functional Outcome of Sleep Questionnaire, and cognitive emotional measures.
RESULTS: A main effect of time was found on diary-measured sleep parameters (decreased sleep onset latency and wake after sleep onset; increased total sleep time and sleep efficiency) and actigraphy-measured sleep parameters (decreased wake after sleep onset; increased sleep efficiency) and daytime functioning (reduced Epworth Sleepiness Scale, Flinders Fatigue Scale; increased Functional Outcome of Sleep Questionnaire) across all arms (all P < .05). Significant interactions and planned contrast comparisons revealed that CBT-I was superior to PAP and self-monitoring on reducing diary-measured sleep onset latency and wake after sleep onset and increasing sleep efficiency, as well as improving Functional Outcome of Sleep Questionnaire and Flinders Fatigue Scale compared to self-monitoring.
CONCLUSIONS: Improvements in sleep and daytime functioning were found with PAP alone or concomitant with CBT-I. However, more rapid effects were observed on self-reported sleep and daytime performance when receiving CBT-I regardless of when it was initiated. Therefore, concomitant treatment appears to be a favorable approach to accelerate treatment outcomes. CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Name: Multidisciplinary Approach to the Treatment of Insomnia and Comorbid Sleep Apnea (MATRICS); URL: https://clinicaltrials.gov/ct2/show/NCT01785303; Identifier: NCT01785303. CITATION: Tu AY, Crawford MR, Dawson SC, et al. A randomized controlled trial of cognitive behavioral therapy for insomnia and PAP for obstructive sleep apnea and comorbid insomnia: effects on nocturnal sleep and daytime performance. J Clin Sleep Med. 2022;18(3):789-800.
© 2022 American Academy of Sleep Medicine.

Entities:  

Keywords:  cognitive behavior therapy for insomnia; comorbid insomnia and sleep apnea; daytime functioning; positive airway pressure therapy; sleep

Mesh:

Year:  2022        PMID: 34648425      PMCID: PMC8883096          DOI: 10.5664/jcsm.9696

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  41 in total

1.  Characterization of Patients Who Present With Insomnia: Is There Room for a Symptom Cluster-Based Approach?

Authors:  Megan R Crawford; Diana A Chirinos; Toni Iurcotta; Jack D Edinger; James K Wyatt; Rachel Manber; Jason C Ong
Journal:  J Clin Sleep Med       Date:  2017-07-15       Impact factor: 4.062

2.  Wake detection capacity of actigraphy during sleep.

Authors:  Jean Paquet; Anna Kawinska; Julie Carrier
Journal:  Sleep       Date:  2007-10       Impact factor: 5.849

3.  Validation of the Flinders Fatigue Scale as a measure of daytime fatigue.

Authors:  Kate Cameron; Paul Williamson; Michelle A Short; Michael Gradisar
Journal:  Sleep Med       Date:  2016-12-03       Impact factor: 3.492

4.  Randomized controlled trial of an integrated approach to treating insomnia and improving the use of positive airway pressure therapy in veterans with comorbid insomnia disorder and obstructive sleep apnea.

Authors:  Cathy A Alessi; Constance H Fung; Joseph M Dzierzewski; Lavinia Fiorentino; Carl Stepnowsky; Juan C Rodriguez Tapia; Yeonsu Song; Michelle R Zeidler; Karen Josephson; Michael N Mitchell; Stella Jouldjian; Jennifer L Martin
Journal:  Sleep       Date:  2021-04-09       Impact factor: 5.849

5.  Insomnia complaints in patients evaluated for obstructive sleep apnea.

Authors:  Suzanne B Krell; Vishesh K Kapur
Journal:  Sleep Breath       Date:  2005-09       Impact factor: 2.816

Review 6.  Comorbid insomnia and obstructive sleep apnea: challenges for clinical practice and research.

Authors:  Faith S Luyster; Daniel J Buysse; Patrick J Strollo
Journal:  J Clin Sleep Med       Date:  2010-04-15       Impact factor: 4.062

7.  Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians.

Authors:  Amir Qaseem; Devan Kansagara; Mary Ann Forciea; Molly Cooke; Thomas D Denberg
Journal:  Ann Intern Med       Date:  2016-05-03       Impact factor: 25.391

8.  Evaluating the treatment of obstructive sleep apnea comorbid with insomnia disorder using an incomplete factorial design.

Authors:  Megan R Crawford; Arlener D Turner; James K Wyatt; Louis F Fogg; Jason C Ong
Journal:  Contemp Clin Trials       Date:  2015-12-28       Impact factor: 2.226

9.  Frequency of insomnia report in patients with obstructive sleep apnoea hypopnea syndrome (OSAHS).

Authors:  Simon Smith; Karen Sullivan; Wendy Hopkins; James Douglas
Journal:  Sleep Med       Date:  2004-09       Impact factor: 3.492

Review 10.  Sleep Apnea and Insomnia: Emerging Evidence for Effective Clinical Management.

Authors:  Jason C Ong; Megan R Crawford; Douglas M Wallace
Journal:  Chest       Date:  2020-12-10       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.